Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

Recruiting now

Conditions studied: Severe Asthma

In brief

This study is an observational multicenter cross-sectional study. Planned study population consists of 5 000 adult patients with uncontrolled SA receiving treatment according to standard of care (except biologics). Planned number of study site is 50 outpatient centers with experience of uncontrolled SA treatment in about 50 regions of Russia (in order to describe characteristics of patients with uncontrolled SA in different regions in the most comprehensive way). This non-interventional study does not imply any intervention into a routine clinical practice, and does not provide for any diagnostic and therapeutic procedures other than those used in routine practice.

Key facts

Study ID: NCT06472310
Run by: AstraZeneca
People needed: 5000
Starts: 2024-06-06
Expected to finish: 2027-06-30
Last updated by the study team: 2026-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥ 18 years at the time of inclusion;
Signed and dated written informed consent in accordance with ICH GCP and local law prior to inclusion in the study;
Patients with diagnosis of uncontrolled SA (Asthma Control Questionnaire-5 (ACQ-5) score > 1,5) established no less than 52 weeks prior to inclusion; Severe asthma is defined as asthma, that is controlled due to treatment with ICS in medium or high doses plus LABA and/or ALP, and/or LAMA, and/or systemic corticosteroids (sCS), and/or immunobiological therapy, while attempts to reduce the volume of therapy lead to a loss of symptom control, or asthma remains uncontrolled despite this treatment. Such therapy should be carried out at least 3 months before inclusion.
Uncontrolled asthma is defined as ACQ-5>1.5.
Patients with the availability of at least 52 weeks of follow-up data (prior to inclusion) in the medical records.

You may not qualify if…

Patients receiving any biological therapy currently or within 52 weeks prior to inclusion;
Presence of chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (ILF) currently or in the anamnesis;
The participation in any clinical study currently or within 52 weeks prior to inclusion;
An acute or chronic disease that, as deemed by Investigator, limits the ability of patients to participate in this study or could influence the interpretation of the results.

Where it is running

Research Site — Irkutsk, Russia (enrolling)
Research Site — Izhevsk, Russia (enrolling)
Research Site — Kazan', Russia (enrolling)
Research Site — Kemerovo, Russia (enrolling)
Research Site — Khabarovsk, Russia (enrolling)
Research Site — Krasnodar, Russia (enrolling)
Research Site — Krasnoyarsk, Russia (enrolling)
Research Site — Moscow, Russia (enrolling)
Research Site — Murmansk, Russia (enrolling)
Research Site — Nal'chik, Russia (enrolling)
Research Site — Nizhny Novgorod, Russia (enrolling)
Research Site — Novosibirsk, Russia (enrolling)
Research Site — Omsk, Russia (enrolling)
Research Site — Orenburg, Russia (enrolling)
Research Site — Petrozavodsk, Russia (enrolling)
Research Site — Rostov-on-Don, Russia (enrolling)
Research Site — Ryazan, Russia (enrolling)
Research Site — Saint Petersburg, Russia (enrolling)
Research Site — Samara, Russia (enrolling)
Research Site — Saratov, Russia (enrolling)
Research Site — Stavropol, Russia (enrolling)
Research Site — Tomsk, Russia (enrolling)
Research Site — Ufa, Russia (enrolling)
Research Site — Ulan-Ude, Russia (enrolling)
Research Site — Verkhnyaya Pyshma, Russia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.